These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 43165)

  • 41. [Protective effect of labetalol on cardiovascular consequences of brain death in the swine].
    Mertes PM; el-Abbassi K; Siaghy EM; Delophont P; Michel C; Longrois-Undergureanu D; Carteaux JP; Villemot JP
    Ann Fr Anesth Reanim; 1997; 16(2):126-30. PubMed ID: 9686073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status of labetalol, the first alpha- and beta-blocking agent.
    Kanto JH
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):617-28. PubMed ID: 2867049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Labetalol (Trandate). an antihypertensive agent with both alpha and beta receptor blockading effects].
    Rasmussen S; Andreasen PB
    Ugeskr Laeger; 1980 Mar; 142(13):839-41. PubMed ID: 6102812
    [No Abstract]   [Full Text] [Related]  

  • 44. The cardiovascular and uterine effects of labetolol in conscious normotensive pregnant rats [proceedings].
    Whalley ET
    Br J Pharmacol; 1977 Nov; 61(3):505P. PubMed ID: 588847
    [No Abstract]   [Full Text] [Related]  

  • 45. Neuropharmacological actions of labetalol.
    Dadhich AP; Khanna NK; Vyas DS; Jain P
    Indian J Physiol Pharmacol; 1979; 23(1):39-43. PubMed ID: 437873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The effect of proxodolol on systemic and regional hemodynamics].
    Dolgun OV; Martynova ER; Medvedev OS; Iuzhakov SD
    Eksp Klin Farmakol; 1994; 57(3):33-6. PubMed ID: 7914116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of temperature on the alpha-adrenoceptor antagonist potency of indoramin and labetalol in the rat perfused mesenteric vascular bed.
    McAdams RP
    J Pharm Pharmacol; 1984 Sep; 36(9):628-9. PubMed ID: 6149291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.
    Svendsen TL; Rasmussen S; Hartling OJ; Nielsen PE; Trap-Jensen J
    Eur J Clin Pharmacol; 1980 Jan; 17(1):5-11. PubMed ID: 7371699
    [No Abstract]   [Full Text] [Related]  

  • 49. [Labetalol: a new hypotensive agent in surgery of the middle ear. Peroperative hemodynamic study].
    Bertrand D; Guyon D; Maday T; Laxenaire MC
    Ann Fr Anesth Reanim; 1982; 1(4):387-92. PubMed ID: 7171135
    [No Abstract]   [Full Text] [Related]  

  • 50. The effect of labetalol on the cardiovascular, hyperglycaemic and adrenocortical responses to surgery.
    Child CS
    Anaesthesia; 1984 Dec; 39(12):1192-6. PubMed ID: 6517247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Labetalol disposition interferes with fluorimetric dosage of catecholamines: in vitro and in vivo trials with enzymatic inhibitors.
    Pisanti N; Vacca M; De Natale G; Preziosi P
    Pharmacol Res Commun; 1980 Nov; 12(10):937-44. PubMed ID: 7443748
    [No Abstract]   [Full Text] [Related]  

  • 52. beta 2-Adrenergic agonist effects of medroxalol and labetalol on rat and mouse uterine muscle.
    Woodward JK; Cheng HC
    J Pharm Pharmacol; 1982 Mar; 34(3):193-5. PubMed ID: 6121900
    [No Abstract]   [Full Text] [Related]  

  • 53. Some further evidence for partial agonist activity of labetalol.
    Riley AJ
    Br J Clin Pharmacol; 1980 May; 9(5):517-8. PubMed ID: 6104978
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of food on the bioavailability of labetalol.
    Mäntylä R; Allonen H; Kanto J; Kleimola T; Sellman R
    Br J Clin Pharmacol; 1980 Apr; 9(4):435-7. PubMed ID: 7378263
    [No Abstract]   [Full Text] [Related]  

  • 55. Urinary catecholamines and labetalol.
    Preziosi P; Pisanti N; Brevetti G; Paudice G; Moerman EJ; De Schaepdryver AF
    Arch Int Pharmacodyn Ther; 1978 Dec; 236(2):317-9. PubMed ID: 747482
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of labetalol, an alpha-and beta-adrenoceptor antagonist, on gastric acid and gastrin secretion in man.
    Caldara R; Rampini P; Piepoli V; Borzoi M
    Br J Clin Pharmacol; 1982 Nov; 14(5):744-6. PubMed ID: 7138756
    [No Abstract]   [Full Text] [Related]  

  • 57. Labetalol and urinary catecholamines.
    Harris D; Richards DA
    Br Med J; 1977 Dec 24-31; 2(6103):1673. PubMed ID: 589414
    [No Abstract]   [Full Text] [Related]  

  • 58. Labetalol and urinary catecholamines.
    Kolloch R; Miano L; De Quattro V
    Br Med J; 1979 Jan; 1(6158):268-9. PubMed ID: 421071
    [No Abstract]   [Full Text] [Related]  

  • 59. Labetalol and urinary catecholamines.
    Richards DA; Harris DM; Martin LE
    Br Med J; 1979 Mar; 1(6164):685. PubMed ID: 435730
    [No Abstract]   [Full Text] [Related]  

  • 60. Labetalol and urinary catecholamines.
    Chapman BP; Veitch AG; Shepherd B
    Br Med J; 1978 Feb; 1(6109):364. PubMed ID: 623996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.